The most impacted population of migraine patients
have experienced significant impediments to new
treatments due to cost, coverage, or availability.
payment/coverage denials persist in this highly
impacted group.
The makers/marketers of Aimovig ™ , Amgen
and Novartis, have launched a patient
assistance program, Aimovig Ally ™ , which is
designed to help patients and providers navigate
the prior approval process. Components to this
program could keep the cost of Aimovig ™ as low
30
HeadW ise ®
|
Volume 7, Issue 1 • 2018
as $5 per month for qualified patients. The NHF
applauds this effort and has great hopes that in the
coming months and years, with the availability of
Aimovig ™ and other new treatments for migraine
management, we will see unprecedented relief
for those most impacted by migraine and other
disabling headache disorders. HW